| Drug Name |
Eltrombopag olamine |
| Drug ID |
BADD_D00760 |
| Description |
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. |
| Indications and Usage |
Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction. |
| Marketing Status |
approved |
| ATC Code |
B02BX05 |
| DrugBank ID |
DB06210
|
| KEGG ID |
D03978
|
| MeSH ID |
C520809
|
| PubChem ID |
135449331
|
| TTD Drug ID |
D00PEH
|
| NDC Product Code |
81719-004; 0078-0687; 0078-0697; 62207-971; 0078-0685; 61187-000; 0078-0684; 0078-0972; 11722-051; 52076-6274; 63379-089; 63379-090; 81719-005; 59651-620; 81719-006; 65977-0097; 14501-0018; 81719-007; 0078-0686 |
| UNII |
4U07F515LG
|
| Synonyms |
eltrombopag | Revolade | SB-497 115 | Promacta |
